Related Experiment Video
Updated: Feb 10, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Anticancer Properties of Fenofibrate: A Repurposing Use
Xin Lian1,2, Gang Wang1, Honglan Zhou1
1Department of Urology, the First Hospital of Jilin University; 71 Xinmin Street, Changchun 130021, China.
Abstract:
Cancer is a leading cause of death throughout the world, and cancer therapy remains a big medical challenge in terms of both its therapeutic efficacy and safety. Therefore, to find out a safe anticancer drug has been long goal for oncologist and medical scientists. Among clinically used medicines with no or little toxicity, fenofibrate is a drug of the fibrate class that plays an important role in lowering the levels of serum cholesterol and triglycerides while elevating the levels of high-density lipoproteins. Recently, several studies have implied that fenofibrate may exert anticancer effects via a variety of pathways involved in apoptosis, cell-cycle arrest, invasion, and migration. Given the great potential that fenofibrate may have anticancer effects, this review was to investigate all published works which directly or indirectly support the anticancer activity of fenofibrate. These studies provide evidence that fenofibrate exerted antitumor effects in several human cancer cell lines, such as breast, liver, glioma, prostate, pancreas, and lung cancer cell lines. Among these studies some have further confirmed the possibility and efficacy of fenofibrate anticancer in xenograft mouse models. In the last part of this review, we also discuss the potential mechanisms of action of fenofibrate based on the available information. Overall, we may repurpose fenofibrate as an anticancer drug in cancer treatment, which urgently need further and comprehensively investigated.
Insights
Fenofibrate, a cholesterol-lowering drug, shows promising anticancer effects across various cancer types. Further research is needed to explore its potential as a safe cancer treatment option.
Area of Science:
- Oncology
- Pharmacology
- Drug Repurposing
Background:
- Cancer remains a significant global health challenge, necessitating novel and safe therapeutic strategies.
- Fenofibrate, a fibrate drug, is clinically used for dyslipidemia with a favorable safety profile.
- Emerging research suggests fenofibrate possesses anticancer properties through various mechanisms.
Purpose of the Study:
- To review existing literature on the anticancer activity of fenofibrate.
- To consolidate evidence supporting fenofibrate's potential as an anti-cancer agent.
- To explore the mechanisms underlying fenofibrate's observed antitumor effects.
Main Methods:
- Systematic review of published studies investigating fenofibrate's effects on cancer.
- Analysis of in vitro data from various human cancer cell lines.
- Evaluation of in vivo data from xenograft mouse models.
Main Results:
- Fenofibrate demonstrated antitumor effects in multiple human cancer cell lines, including breast, liver, glioma, prostate, pancreas, and lung.
- Preclinical studies in xenograft mouse models corroborated fenofibrate's anticancer efficacy.
- Identified pathways involved in fenofibrate's action include apoptosis induction and cell-cycle arrest.
Conclusions:
- Fenofibrate exhibits significant potential as an anticancer agent across a spectrum of cancers.
- Repurposing fenofibrate for cancer treatment warrants further comprehensive investigation.
- Fenofibrate represents a promising candidate for developing safer and effective cancer therapies.
Related Concept Videos
Physical and Chemical Properties of Matter
Properties of Transition Metals
General Properties of Solutions
Convolution Properties I
The commutative property reveals that the input and the impulse response of an LTI (Linear Time-Invariant) system can be interchanged without affecting the output:
Properties of DTFT II
The frequency differentiation property is illustrated by considering a DTFT pair and differentiating both sides with respect to ω.
Properties of the z-Transform I

